



Investor Presentation

MARCH-2026

Disclaimer

The material contained in this document is a presentation of general information about the activities of EBR Systems, Inc. (ASX:EBR) (ARBN 654 147 127) and its subsidiaries (“EBR”) current as at the date of this presentation. It should be read in conjunction with EBR’s periodic and continuous disclosure announcements filed with the Australian Securities Exchange, available at www.asx.com.au.

The information in this presentation is provided in a summary form, does not purport to be complete and should not be relied upon as advice for investment purposes. This presentation is for information purposes only and is not financial product advice or a recommendation to acquire EBR securities. This presentation does not take into account the investment objectives, financial position or needs of any particular investor. Independent advice should be sought before making any investment decision.

The information in this presentation has been prepared by EBR in good faith and with due care, but the EBR does not make any representation or warranty, express or implied, as to the fairness, accuracy, correctness or completeness of the information, opinions or conclusions contained in this presentation. The information in this presentation is subject to change without notice and unless required by law, EBR assumes no obligation to update this presentation or its contents for any matter arising or coming to EBR’s notice after the date of this presentation.

Certain statements in this presentation may constitute forward-looking statements or statements about future matters that are based on management’s current expectations and beliefs. Such statements are typically identified by words such as ‘may’, ‘could’, ‘believes’, ‘estimates’, ‘expects’, ‘anticipates’, ‘intends’ and other similar words. These statements are subject to risks and uncertainties that are difficult to predict and are based on assumptions as to future events that may not prove accurate. Actual results

may differ materially from what is expressed in this presentation.

To the maximum extent permitted by law, no responsibility for any loss arising in any way (including by way of negligence) from anyone acting or refraining to act as a result of this presentation or its contents is accepted by EBR or any of its officers, employees or agents.

The distribution of this presentation outside of Australia may be restricted by law and any such restrictions should be observed. This presentation does not constitute an offer to sell, or a solicitation of an offer to buy, securities in Australia, the United States or any other jurisdiction.

Investors should note that this presentation may contain unaudited financial information that has been prepared by EBR’s management. EBR’s results are reported under US GAAP. Certain financial data in this presentation is “non-IFRS financial information” under Regulatory Guide 230 (Disclosing non-IFRS financial information) published by ASIC. All values are stated in U.S. dollars unless otherwise stated.

EBR’s CHES Depositary Interests (“CDIs”) are traded on ASX in reliance on the safe harbour provisions of Regulation S under the US Securities Act of 1933, as amended, and in accordance with the procedures established pursuant to the provisions of a no-action letter dated 7 January 2000 given to ASX by the staff at the US Securities and Exchange Commission. The relief was given subject to certain procedures and conditions described in the no-action letter. One of the conditions is that the issuer provides notification of the Regulation S status of its securities in communications such as this presentation.

Investment Highlights

Listed on ASX (symbol EBR) since 2021 and SEC registrant since 2024

The future of CRT is leadless...EBR's WiSE System is the only device capable of providing fully leadless CRT

Significant Growth Potential



No direct competitors

WiSE System is complementary to other cardiac pacing devices, including leadless pacemakers. WiSE is the only leadless device that can pace the left ventricle for heart failure



Large market opportunity

Targeting an initial addressable market of US\$5.8bn in the US

Barriers Removed



FDA PMA approved


US FDA approval received 11 April 2025 supported by Breakthrough Device Designation and compelling clinical data



Premium reimbursement

CMS approval for both NTAP (inpatient) and TPT (outpatient) at contract price of US\$63,300.

Poised to Scale



Clear commercial strategy

Continued commercial traction during Limited Market Release (LMR) phase, initiated Q4'25. Executed by an experienced team with a track record of scaling early-stage technology




Manufacturing facilities in place

New facility under construction to support commercial growth and improved margins
Expect full transition to new facility by the end of H2 2026

Major Milestones

Proven track record of achieving major clinical, regulatory, and reimbursement milestones




Market Opportunity




Cardiac Rhythm Management Market

Comprised of three key segments

Worldwide CRM Market (US\$18.4bn)¹



- Cardiac Resynchronization Therapy (CRT)
- Implantable Cardioverter Defibrillation (ICD)
- Pacemakers



Leads – The Achilles’ Heel of Cardiac Rhythm Management

Traditional CRT systems use wires or leads to deliver energy to the heart, which can lead to many problems.




Leads can migrate and fracture



Leads can become infected - a pathway for pathogens to reach the myocardium



Cannot be placed inside (endocardially) the left ventricle



Left Ventricle (LV) lead must be placed outside the heart to avoid blood clots



Higher risk of complications with a lead-based upgrade to CRT




Risks increase as the number of leads increases

Market is Rapidly Adopting Leadless Devices as Standard


EBR's WiSE System provides the only option for upgrading leadless pacemakers to totally leadless CRT (TLC)

		EBR	Medtronic	Abbott	Boston Scientific
Leadless Pacing	Left Ventricle Endocardial Pacing (LVEP)	WiSE®			
	Right Atrium (RA) Pacing			Aveir® AR	
	Right Ventricle (RV) Pacing		Micra® VR	Aveir VR	Empower®
	RV Pacing with Atrial Sensing (VDD)		Micra AV		
	RA-RV Dual Chamber Pacing (DDD)			Aveir DR	
Leadless ICD	Defibrillation and Anti-Tachycardia Pacing		Aurora® EV-ICD		Emblem® S-ICD




Targeting a \$5.8bn Total Addressable U.S. Market

Total addressable market represents patients with limited or no other options



Pairing a leadless pacemaker with WiSE provides totally leadless CRT (TLC)

Total Addressable market (US\$5.8bn)¹



Leadless Upgrades
 Patients with a leadless right ventricle pacemaker² where it is deemed high risk to convert to conventional CRT

Fastest growing segment

High Risk Upgrades
 Patient deemed high risk for a conventional CS lead placement

Acute Lead Failure
 Unable to implant CRT lead in a new CRT patient.

Chronic Lead Failure
 Traditional CRT lead fails over time

Commercialisation and Reimbursement



WiSE Reimbursement

As a breakthrough medical device, EBR's WiSE System has been granted to significant reimbursement

Medicare In-patient Payment

New Technology Add-On Payment (NTAP)

- CMS has approved the NTAP payment for WiSE
- Commenced October 2025
- Add-on payments based on \$63,300 ASP

Benefits of NTAP:

- Designed to cover the increased cost of important new technologies
- Reduced financial barriers for sites and improves access
- Validates the technology's innovation and clinical benefit

Medicare Out-patient Payment

Transitional Pass-Through (TPT) Payment

- CMS has approved the TPT payment for WiSE up to \$63,300
- Commenced October 2025

Benefits of TPT:

- Covers cost of WiSE system
- Reduced financial barriers for sites and improves access
- External validation that the technology represents a meaningful clinical advancement

Medicare Coverage

Transitional Coverage of Emerging Technologies (TCET)

- WiSE is **first** technology to be accepted in the TCET program
- Developing Coverage with Evidence (CED) protocol

Benefits of TCET:

- Early CMS engagement for an efficient review process
- Transitional NCD for up to 5 years
- Expedited Medicare coverage

Executing a Clear Commercialisation Strategy



Disciplined approach to commercialisation, limiting execution risk

- ✓ First sales achieved in 2Q '25 during pilot phase
- ✓ Limited Market Release (LMR) began OCT '25 coinciding with initiation of add-on and pass-through payments
- ✓ Focused subset of strategic hospitals to be targeted
- ✓ Significant support and advocacy from US physicians



Continued investment in expanding commercial leadership team and direct sales force


- ✓ Investment into leadership team including appointment of Chief Commercial Officer and 2 VPs of Sales and a VP of Marketing
- ✓ Initiated the LMR with with 8 sales territories in place, each consisting of a sales rep and a clinical / technical specialist
- ✓ Sales force expansion will continue in waves throughout 2026

Early Commercial Traction/KPIs

Limited market release starts with trained salespeople, who then engage physicians, followed by hospital contracting negotiations, leading to treated patients and revenue


Physician Engagement

Physicians Trained




Site Negotiation and Contracting

Purchasing Contracts Signed



Patients Treated and Revenue

Cases Completed



Early commercial traction reinforces that EBR has a repeatable sales model with significant demand from both patients and physicians

World Class Manufacturing Facility

EBR is building out a new state-of-the-art facility to support long-term commercial growth and scale

Significant Facility Expansion

- New 11-year lease secured for 51,000 sq ft (4,751 sqm) facility
- Expansion of capability from critical manufacturing processes to manufacture of complete units
- Expands EBR's manufacturing capacity to accommodate future growth and demand for WiSE

Excellent Economics

- Rent payments deferred until January 2026
- Gradual space occupancy and rent scaling up annually to full occupancy by year four
- Landlord to finance approximately US\$4m in tenant improvements

Timing

- Facility upgrades and qualifications to be completed progressively over 2026 with personnel transitioning to the new facility beginning Q2 2026 and manufacturing fully transferred by year end



State-of-the-art facility in Santa Clara, California

Leadership, Financials and Outlook



Summary Financials

Select summary financial data – figures in \$K

Line Item	4Q 2025	3Q 2025**	2Q2025**
Quantity - Commercial Implants	18*	9	3
Revenue	\$ 870 – 935*	\$ 512	\$ 170
Gross Profit	***	224	85
Gross Profit %	***	43.8%	50.0%
Operating Expenses	***	12,105	11,216
Net Loss	***	(12,189)	(11,967)
Cash & Marketable Securities On Hand	***	\$ 70,396	\$ 84,598

- 100% implant volume growth 4Q 2025 v 3Q 2025
- Revenue figure includes implants, battery replacements, and surgical tools

* Per EBR Form 8-K filed January 9, 2026

** Per EBR Form 10-Q

*** 4Q 2025 figures to be disclosed with release of EBR 2025 Form 10-K during mid-March 2026

Leadership Team



John McCutcheon
PRESIDENT & CHIEF EXECUTIVE OFFICER

- CEO since 2019
- 40+ years of sales, marketing and leadership experience in med device
- Lengthy CEO and M&A background



Gary Doherty
CHIEF FINANCIAL OFFICER

- CFO since 2023
- 35+ years of finance and accounting experience
- Led 2020 Nasdaq IPO for Acutus Medical



Erik Strandberg
CHIEF COMMERCIAL OFFICER

- CCO since 2024
- Over two decades of med device sales experience and related leadership
- Strategic planning and product portfolio management



Michael Hendricksen
CHIEF OPERATING OFFICER

- COO since 2021
- Extensive product development and manufacturing experience, scaling and integrating operations



Pharoah Garma
CHIEF REGULATORY OFFICER

- CRO since 2024
- Sr. FDA Reviewer prior to leadership roles at various startups and multinationals.
- COO at Boomerang Medical



Spencer H. Kubo, M.D.
MEDICAL MONITOR

- CMO 2019-2025
- Lengthy experience as CMO, in clinical trial oversight, and in various academic roles



Andrew Shute
CHIEF CORPORATE DEVELOPMENT OFFICER

- SVP Global Field Ops / CCDO since 2015
- Strong clinical training and sales experience
- Integral role in investor relations



N. Parker Willis
CHIEF TECHNOLOGY OFFICER

- CTO since 2011
- Extensive signal processing experience in medical devices and development for novel cardiac EP



Board of Directors:	Allan Will EXECUTIVE CHAIRMAN	Bronwyn Evans, Ph.D. DIRECTOR	Christopher Nave, Ph.D. DIRECTOR	Karen Drexler DIRECTOR	Trevor Moody DIRECTOR	David Steinhaus, M.D. DIRECTOR	John McCutcheon DIRECTOR, PRESIDENT & CEO
---------------------	----------------------------------	----------------------------------	-------------------------------------	---------------------------	--------------------------	-----------------------------------	--

Outlook – next 6-12 months

- Quarter-over-quarter revenue growth
- Continuing engagement and education of hospital administrators on NTAP and TPT reimbursement
- Additional hiring and training of field sales team
- Expansion into additional US hospitals in line with phased commercial strategy
- Growth in utilisation rate at early implanting hospitals as experience builds
- Focus on quality systems, supply chain readiness and scalability to support commercial growth
- Completion of buildout and qualification of new manufacturing facility to support expansion of manufacturing capability and capacity

Investment Summary

The future of CRT is leadless. WiSE is the only device able to providing truly leadless solution for CRT.



Developer of the world's first and only leadless pacing system for heart failure



EBR's WiSE[®] System has no direct competitors and is complementary to other pacemaker technologies




FDA approved with premium reimbursement in place



Significant market opportunity with an initial addressable market of \$5.8bn



Commercialisation is accelerating in key hospitals. Clear strategy in place, focusing on high-volume sites in the US. Executed by a commercial team proven track record of scaling early-stage companies



Contact:

Company

Andrew Shute

Chief Corporate Development Officer

P: +44 7730 691421

E: info@ebrwise.com

Investors

Gabriella Hold

The Capital Network

P: +61 2 8999 3699

E: gaby@thecapitalnetwork.com.au

www.ebrsystemsinc.com

Appendix



References

- Grand View Research (2025). Cardiac Rhythm Management Devices, Market Estimates & Trend Analysis From 2021 to 2033
- Lin G, Anavekar N, Webster T, et al. Long-term Stability of Endocardial Left Ventricular Pacing Leads Placed via the Coronary Sinus. *PACE* 2009;32:1117-1122
- Curtis AB, Worley SJ, Adamson PB, et al; for the BLOCK HF Trial Investigators. Biventricular pacing for atrioventricular block and systolic dysfunction. *N Engl J Med*. 2013;368(17):1585-1593.
- Ahsan S, Saberwal B, Lambiase P, et al. An 8-year single-centre experience of cardiac resynchronisation therapy: Procedural success, early and late complications, and left ventricular lead performance. *Europace* 2013;15:711-717
- Al-Majed NS, McAlister FA, Bakal JA, Ezekowitz JA. Meta-analysis: cardiac resynchronization therapy for patients with less symptomatic heart failure. *Ann Intern Med*. 2011;154(6):401-412.
- Virani S, Alonso A, Benjamin E, et al. Heart Disease and stroke statistics – 2020 update: A report from the American Heart Association. *Circulation*. 2020;141(9):139-596
- Ponnusamy SS, Syed T, Vijayaraman P. Pacing induced cardiomyopathy: recognition and management. *Heart* 2023;109:1407-1415.
- Glikson M, Nielsen J, Kronborg M, et al. 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. *Eur Heart J* 2021;00:1-94
- Bogale N, Witte K, Priori S, et al. The European Cardiac Resynchronization Therapy Survey: comparison of outcomes between de novo cardiac resynchronization therapy implantations and upgrades. *Eur J HF* 2011;13:974-983
- Abu-El-Haija B, Bhave P, Campbell D, et al. Venous Stenosis After Transvenous Lead Placement: A Study of Outcomes and Risk Factors in 212 Consecutive Patients. *J Am Heart Assoc* 2015;4:e001878
- Kiehl E, Makki T, Kumar R, et al. Incidence and predictors of right ventricular pacing-induced cardiomyopathy in patients with complete atrioventricular block and preserved left ventricular systolic function. *Heart Rhythm* 2016;13:2272-2278
- Friedman DJ, Qin L, Freeman JV, et al. Left ventricular lead implantation failure in an unselected nationwide cohort. *Heart Rhythm*. 2023;20(10):1420-1428
- Hakemi EU, Doukky R, Parzynski CS, Curtis JP, Madias C. Quadripolar versus bipolar leads in cardiac resynchronization therapy: An analysis of the National Cardiovascular Data Registry. *Heart Rhythm*. 2020;17(1):81-89
- Gamble, J, Herring, N, Ginks, M. et al. Procedural Success of Left Ventricular Lead Placement for Cardiac Resynchronization Therapy: A Meta-Analysis. *J Am Coll Cardiol EP*. 2016; Feb, 2 (1):69–77.
- Brignole M, Auricchio A, Baron-Esquivias G, et al. 2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: The Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association. *Eur Heart J* 2013;34:2281-2329
- El-Chami M, Garweg C, Clementy N, et al. Leadless pacemakers at 5-year follow-up: the Micra transcatheter pacing system post-approval registry. *Eur Heart J* 2024;45:1241-1251
- Johansen J, Jørgensen O, Møller M, et al. Infection after pacemaker implantation: infection rates and risk factors associated with infection in a population-based cohort study of 46299 consecutive patients. *Eur Heart J* 2011;32:991-998
- Merchant F, Hoskins M, Musat D, et al. Incidence and Time Course for Developing Heart Failure With High-Burden Right Ventricular Pacing. *Circ Cardiovasc Qual Outcomes*. 2017;10:e003564
- Mendoca-Costa C, Neic A, Gillette K, et al. Left ventricular endocardial pacing is left arrhythmogenic than conventional epicardial pacing when pacing in proximity to scar. *Heart Rhythm* 2020;17:1262-1270
- Vamos M, Erath J, Bari Z, et al. Effects of Upgrade Versus De Novo Cardiac Resynchronization Therapy on clinical Response and Long-Term Survival, Results from a Multicenter Study. *Circ Arrhythm Electrophysiol*. 2017;10:e004471